Two Mature Platforms, Two Different Profiles
Lipid nanoparticles and biodegradable polymeric nanoparticles are both well-established pharmaceutical delivery platforms with approved products and substantial clinical track records. LNPs are the platform behind the COVID-19 mRNA vaccines, liposomal doxorubicin, and a growing range of nucleic acid therapeutics. Polymeric nanoparticles, particularly those based on PLGA and PLA, have been approved in long-acting injectable formulations including the goserelin depot (Zoladex) and have a strong development pipeline across oncology, neurology, and infectious disease.
Choosing between them is not always straightforward. Both can encapsulate small molecule APIs and both can be engineered for sustained release. The decision depends on the physicochemical properties of the molecule, the intended route of administration, the target release profile, the regulatory pathway, and the manufacturing infrastructure available at the development partner.
Head-to-Head Platform Comparison
| Factor | Lipid Nanoparticles (LNP) | PLGA Polymeric Nanoparticles |
| Primary payload types | Nucleic acids (mRNA, siRNA, DNA); small molecules; peptides | Small molecules; peptides; proteins; hydrophilic and hydrophobic drugs |
| Release profile | Typically rapid; burst release unless specifically engineered for sustained delivery | Tunable sustained release from days to months based on polymer MW and composition |
| Biodegradability | Lipid components metabolised via natural lipid pathways | Hydrolytic degradation to lactic acid and glycolic acid; natural metabolites |
| Stability in circulation | Ionisable LNPs designed for stability in blood; PEGylation extends circulation half-life | PLGA NPs stable in circulation; surface properties affect protein adsorption and clearance |
| Administration routes | IV (oncology, nucleic acid); IM (vaccines); potentially inhaled | IM/SC depot (sustained release); IV; potentially oral |
| Manufacturing technology | Microfluidics; extrusion; established at GMP scale | Nanoprecipitation; emulsion-solvent evaporation; established at GMP scale |
| Regulatory precedent | Strong: Onpattro (siRNA LNP), mRNA vaccines, Doxil (liposome) | Strong: Lupron Depot, Zoladex (PLGA microspheres); growing body for nanoparticles |
| Best suited for | Nucleic acid delivery; rapid onset injectables; vaccines | Sustained release injectables; small molecule payloads; depot formulations |
When LNPs Win
If your payload is a nucleic acid, the case for an LNP platform is essentially settled. The ionisable lipid system is specifically designed to encapsulate negatively charged nucleic acids at high efficiency, protect them from enzymatic degradation in the extracellular environment, and facilitate endosomal escape after cellular uptake. No polymer nanoparticle system has demonstrated equivalent nucleic acid delivery efficiency in systemic applications.
For small molecule payloads that need rapid release, such as anti-cancer agents that need to achieve high intracellular concentrations quickly after uptake, LNPs also have an advantage over slowly degrading PLGA systems. The clinical success of liposomal doxorubicin (Doxil) in extending the circulation half-life of the drug while reducing cardiotoxicity relative to free doxorubicin is a demonstration of this principle.
When Polymeric Nanoparticles Win
For programmes where the clinical objective requires drug release over days, weeks, or months from a single injection, PLGA-based systems have an advantage that is difficult to replicate with LNPs. The tunable degradation rate of PLGA, combined with well-characterised manufacturing processes for microspheres and nanoparticles, makes it the platform of choice for depot injectable programmes where patient compliance with daily dosing is a limiting factor.
For small molecule payloads where stability in an aqueous lipid environment is a concern, encapsulation within a solid polymer matrix can offer better protection than an LNP core. Hydrophilic molecules that do not partition efficiently into the lipid phase of an LNP also tend to be better suited to polymer matrix systems that can encapsulate them within an aqueous core or adsorb them to a polymer surface.
Ardena’s Dual Platform Capability at Oss
Ardena’s nanomedicine team at Oss has development and GMP manufacturing capabilities for both LNP and polymeric nanoparticle platforms. The team can advise on platform selection based on the molecule’s physicochemical profile and the programme’s clinical and regulatory objectives, and can design feasibility studies that compare platform options before a full development programme is committed to a single technology.
